Treatment of Systemic Lupus Erythematosus (SLE)

Treatment Flowchart

Recommended drugs for SLE stratified by disease severity - Firestein & Kelley's Textbook of Rheumatology (2022)

1. Hydroxychloroquine (HCQ) - Universal Backbone

• Dose: Must not exceed 5 mg/kg real body weight/day (to minimize retinal toxicity)
• Ophthalmologic screening: At baseline, 5 years after starting, then annually
• Benefits: Controls skin disease, arthritis, serositis, and mild hematologic abnormalities; reduces risk of flares, end-stage renal disease, type 2 diabetes, venous thromboembolism, and cardiovascular events; improves overall SLE survival
• Mechanism: Reduces lysosomal activity, inhibits MHC class II antigen presentation, and blocks TLR7/TLR9 signaling
• Safety in pregnancy: Not teratogenic; continued during pregnancy to prevent flares

2. Mild SLE (Skin, Joints, Mucosal)

3. Moderate-to-Severe SLE

Glucocorticoids

• Oral or IV GCs are used for rapid disease control
• Goal: Taper to prednisone ≤ 5 mg/day (remission target) or ≤ 7.5 mg/day (low disease activity target)
• High-dose IV methylprednisolone "pulse" therapy (500-1000 mg/day x 3 days) for severe flares

Immunosuppressants

• Mycophenolate mofetil (MMF): 2-3 g/day; first-line for lupus nephritis (LN) and extrarenal moderate-severe SLE; comparable or superior to cyclophosphamide with better tolerability; strongly teratogenic
• Azathioprine (AZA): 2-3 mg/kg/day; used in mild-moderate disease and as maintenance; safe in pregnancy (unlike MMF)
• Methotrexate (MTX): Useful for musculoskeletal and mucocutaneous manifestations

4. Severe/Organ-Threatening SLE - Cyclophosphamide (CYC)

• Initial dose: 0.75 g/m² IV (reduce to 0.5 g/m² if GFR < 1/3 normal)
• Monthly pulses for 6 months (7 total pulses)
• Adjust to keep WBC nadir > 1500/mm³; max dose 1 g/m²
• Bladder protection: Vigorous hydration + mesna (20% of CYC dose) to prevent hemorrhagic cystitis
• Key toxicities: Myelosuppression, gonadal toxicity (premature ovarian failure), infections (especially herpes zoster), bladder carcinoma

5. Biologic Agents

Belimumab (anti-BAFF/BLyS monoclonal antibody)

• FDA-approved for active SLE and active lupus nephritis
• Consider when: persistent disease activity or frequent flares despite standard of care; unable to taper GCs to acceptable dose; add-on to standard therapy in LN
• Given IV or subcutaneously

Anifrolumab (anti-interferon-α/β receptor antibody)

• FDA-approved for moderate-to-severe nonrenal SLE on background standard therapy
• Targets the type I interferon pathway, which is hyperactivated in most SLE patients

Rituximab (anti-CD20 B-cell depleting antibody)

• Reserved for severe or refractory SLE - not FDA-approved for SLE but widely used off-label
• Useful in refractory LN, severe cytopenias, neuropsychiatric SLE

Obinutuzumab (next-generation anti-CD20)

• Phase 3 trials ongoing for proliferative LN; showed superior complete renal response vs. placebo in the NOBILITY phase 2 trial (35% vs. 23% at 52 weeks) - PMID 39927615

6. Lupus Nephritis - Specific Approach

• Add voclosporin (calcineurin inhibitor, CNI) or belimumab to MMF/GC induction for enhanced renal response (approved combinations)
• HCQ continued throughout; reduces risk of end-stage renal disease even in LN

7. Antiphospholipid Syndrome (aPL-positive SLE)

• Low-dose aspirin (antiplatelet) for primary prevention
• Long-term anticoagulation (warfarin, target INR 2-3) for patients with thrombotic events
• Avoid direct oral anticoagulants (DOACs) in triple-positive aPL

8. Adjunct/Supportive Measures

• Sun protection (UV triggers flares)
• Vaccinations (especially influenza, pneumococcus, COVID-19) - avoid live vaccines on immunosuppression
• Smoking cessation, weight control, BP/lipid/glucose management
• Nephroprotective agents in LN: ACE inhibitors or ARBs to reduce proteinuria
• Calcium + vitamin D supplementation on chronic steroids
• Osteoporosis prophylaxis with bisphosphonates if on long-term GCs

Treatment Targets

• Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set (2022), Chapter 82
• Goldman-Cecil Medicine International Edition (2022), Chapter on Immunomodulatory Agents
• Recent RCT: Obinutuzumab in LN - Furie et al., NEJM 2025 [PMID 39927615]